Given that the interaction between AlaRS mutants and Nrp1 is associated with disease progression in CMT, the ability of Tanshinone I to disrupt this binding highlights its potential to intervene in the pathogenic mechanisms of these diseases. Here, NRP1 is linked to Charcot-Marie-Tooth disease.